Sep 30, 2026BioNTech to close three sites in Germany | Lifecore to be acquired for $663.7M

Sep 29, 2026China’s manufacturing of FDA-approved drugs on rise | Vetter boosts fill-finish capacity

Sep 26, 2026Lilly vs. Novo in oral GLP-1 race | WuXi Biologics passes another FDA GMP inspection

Sep 25, 2026Data hurdles remain in AI-based pharma manufacturing | Altruist Biologics gets EMA GMP certification

Sep 24, 2026CDMOs invest in European API capabilities | WuXi XDC’s Singapore site marks GMP release

Sep 23, 2026Novo says manufacturing network ready for demand | Lilly breaks ground on $6.5B API facility

Sep 22, 2026Canada’s largest biomanufacturing investment | Resilience sells PA cell therapy site

Sep 19, 2026AI, bioreactors improve enzyme production | Cellares teams with cell therapy developer

Sep 18, 2026Cellares plots strategy post-BMS partnership | Neuland expands peptide capacity

Sep 17, 2026Thermo Fisher benefits from US reshoring | Hovione doubles US spray drying capacity

Sep 16, 2026Ori targets commercial cell therapy manufacturing | Asahi Kasei's gene therapy benchtop

Sep 15, 2026Merck’s mix of biologics, small molecules | Shilpa’s new small molecule CDMO

Sep 12, 2026Are CDMOs up to the challenge? | Transcenta, WuXi Biologics ink licensing deal

Sep 11, 2026Catalent’s debt refinancing, investment | Samsung nabs $262M manufacturing deal

Sep 10, 2026Sandoz’s European biosimilar hub | Charles River expands automated manufacturing suite

Sep 9, 2026Scaling radiopharma manufacturing | AtomVie’s $160M radiopharma CDMO facility

Sep 5, 2026Foreign-headquartered CMOs expand US capacity | Curia’s Albuquerque expansion

Sep 4, 2026Evonik bolsters North America network | Lifecore secures commercial site transfer agreement

Sep 3, 2026ARPA-H funds genetic medicines on demand | Andelyn scales gene therapy manufacturing

Sep 2, 2026Trump’s 9 new drug pricing, tariff deals | Syntegon opens OSD customer center

Sep 1, 2026Continuous upstream bioprocessing grows | WuXi XDC’s Singapore site achieves milestone

Aug 29, 2026Samsung Biologics to raise $2.2B | BMS to build $173M Indiana radiopharma plant

Aug 28, 2026WuXi Biologics expands capacity | Artis BioSolutions’ new genetic medicines center

Aug 27, 2026What’s next for Cellares after losing BMS? | Aurigene inks deal with global pharma company

Aug 26, 2026BMS ends partnership with Cellares | Cambrex’s NC site clears inspections

Latest Edition